KA/EN
Register
Medicines reference
Search
Search
Active substance

Buprenorphine

Favourites

Opioid (partial µ agonist). No registration in force in Georgia. Forms: solution.

Controlled substance. For use only by a veterinarian, as the law prescribes.
Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Buprenorphine
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
10–20 mcg/kg Dog Postoperative Pain
Analgesia
 Intravenous / Intramuscular every 3–4 hours at 10 micrograms/kg or every 5–6 hours at 20 micrograms/kg
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Vetergesic Multidose 0.3 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Vetergesic 0.3 mg/ml Solution for Injection for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
10–20 mcg/kg Dog Sedation Intramuscular once, as premedication
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Vetergesic Multidose 0.3 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
10–20 mcg/kg Cat Postoperative Pain
Analgesia
 Intravenous as needed; repeat once after 1–2 hours
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Vetergesic Multidose 0.3 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
10–20 mcg/kg Cat Postoperative Pain
Analgesia
 Intramuscular as needed; repeat once after 2 hours
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Vetergesic 0.3 mg/ml Solution for Injection for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Before use

Safety information

Known Contraindications

  • Critical
    Known hypersensitivity to buprenorphine or any excipient is a contraindication.
  • Warning
    Do not use buprenorphine before caesarean section because it can cause respiratory depression in the offspring around birth. Use cautiously during pregnancy and, if needed after surgery, monitor the dam and neonates closely.
  • Warning
    Buprenorphine is not recommended during lactation because concentrations in milk can equal or exceed plasma concentrations.
  • Warning
    Buprenorphine can cause respiratory depression. Use cautiously in animals with impaired respiratory function or in those receiving other drugs that depress respiration.
  • Warning
    Use buprenorphine cautiously in hepatic impairment, especially biliary-tract disease, because hepatic metabolism affects the intensity and duration of its action.
  • Warning
    Buprenorphine carries greater risk in renal, cardiac, or hepatic dysfunction and in shock. Use only after a careful benefit-risk assessment with appropriate monitoring.
  • Warning
    Use buprenorphine cautiously in cardiac dysfunction or shock because cardiovascular adverse effects, including bradycardia and occasionally hypertension or tachycardia, may occur.
  • Caution
    Do not administer buprenorphine intrathecally or epidurally. Opioid antagonists may not fully reverse its effects; naloxone can help with respiratory depression but repeated dosing or infusion may be required because buprenorphine is long acting.
  • Caution
    Safety of buprenorphine has not been established in animals younger than 7 weeks.

Known Drug Interactions

  • Major warning Methadone + Buprenorphine
    Do not combine buprenorphine with morphine or other opioid analgesics, including fentanyl, pethidine, methadone, or butorphanol, because their analgesic effects may be unpredictable or antagonistic.
    Recommendation: Do not administer concurrently; buprenorphine may antagonize a mu-opioid agonist.
  • Minor warning Buprenorphine + Acepromazine
    Centrally acting drugs, including tranquillisers, sedatives, and hypnotics, can increase buprenorphine-induced drowsiness. Combined use with sedatives can also increase depression of heart rate and respiration.
    Recommendation: Reduce the sedative dose during premedication; monitor heart rate and respiration.
  • Minor warning Buprenorphine + Dexmedetomidine
    Centrally acting drugs, including tranquillisers, sedatives, and hypnotics, can increase buprenorphine-induced drowsiness. Combined use with sedatives can also increase depression of heart rate and respiration.
    Recommendation: Reduce the sedative dose during premedication; monitor heart rate and respiration.
Latin name
Buprenorphine
Georgian name
ბუპრენორფინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
0 of 1 forms
Products
Vetergesic Multidose
Controlled in Georgia
Yes
Listed under the Georgian narcotics law (Annex 1) or the Minister's Order No. 22/n. The legal text is in Georgian.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Vetergesic Multidose 0.3 mg/ml, Solution

solution for injection for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Perioperative/postoperative analgesia with exact Vetergesic Multidose 0.3 mg/ml
7.6/10
Good
vetman assessment

Vetergesic Multidose

0.3 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeDog · Perioperative/postoperative analgesia with exact Vetergesic Multidose 0.3 mg/ml · IM,IV
Care settingVeterinary perioperative care with controlled-drug custody, multimodal analgesia, formal pain scoring and cardiorespiratory monitoring
vetman score 7.6/10 Good
Evidence confidence: Medium Georgia: No · Verified on 22 Oct 2026

A well-defined authorised clinic opioid with useful IM/IV flexibility and credible canine evidence; best within monitored multimodal analgesia, not as an automatic sole analgesic.

Regulatory and scientific credibility9.0/10

Exact current GB/European authorisations identify Ceva, the 10 ml multidose formulation, dog/cat species and IM/IV routes. The exact product is absent in GE/US.

Clinical efficacy7.5/10

The exact postoperative and sedation-potentiation label, guidelines and direct canine studies support efficacy, but rescue needs vary and multimodal use is preferable.

Safety and tolerability6.5/10

Established monitored opioid use, but respiratory/cardiovascular depression, variable response, organ-dysfunction cautions, interactions and incomplete antagonist reversal constrain safety.

Clinical practicality7.0/10

IM/IV flexibility and a multidose vial suit hospital use. Tiny microgram doses require an accurately graduated syringe, strict repeat logic and controlled-drug governance; clinic administration itself is not penalised.

Full-course cost-effectiveness-

Current exact Georgian price/availability and a comparable treatment-period cost are not verified; cost is excluded.

Important safety and use flags

  • MICROGRAMS, not milligrams: 10–20 micrograms/kg equals 0.01–0.02 mg/kg and 0.03–0.06 ml/kg of this 0.3 mg/ml product. A unit error can be catastrophic.
  • This is exact Vetergesic Multidose: 10 ml vial, chlorocresol preservative, IM/IV. Do not substitute the separate IM-only 1 ml ampoules or US Simbadol/Zorbium concentrations and regimens.
  • Dog repeat timing depends on the administered dose: 10 microgram/kg after 3–4 hours or 20 microgram/kg after 5–6 hours. Reassess pain; an alternative class may be needed rather than automatic repetition.
  • Use formal pain scoring and multimodal analgesia. Individual opioid response varies and a repeat dose may fail; provide rescue analgesia rather than accepting uncontrolled pain.
  • Monitor respiratory rate/effort, oxygenation, heart rate, blood pressure, temperature, sedation and recovery. Risk rises with impaired respiration, shock or renal, cardiac, hepatic/biliary dysfunction.
  • Do not administer intrathecally or epidurally, and do not use pre-operatively for caesarean section. Lactation use is not recommended; pregnancy requires a benefit-risk decision.
  • Other centrally acting sedatives can augment heart-rate and respiratory depression; reduce companion sedative doses and monitor. Do not combine casually with other opioids, including methadone or butorphanol.
  • Naloxone or respiratory stimulants may help, but opioid antagonists may not fully reverse buprenorphine and repeat dosing/infusion can be needed because of its duration. Support ventilation and circulation.
  • Sedation, bradycardia and occasionally hypertension/tachycardia can occur. Premedication can reduce anaesthetic requirements, so adjust the whole protocol rather than considering each drug independently.
  • This is a high-risk controlled opioid. Maintain lawful procurement, secure storage, access/usage logs, reconciliation and witnessed disposal. Product registration does not remove controlled-drug obligations.
Assessment sources
  1. VMD SPC 20252025
  2. Vetergesic Multidose VMD record2026
  3. Vetergesic Multidose UPD record2026
  4. Vetergesic ampoule comparator2025
  5. WSAVA pain guideline 20222022
  6. Canine Vetergesic RCT2018
  7. Canine buprenorphine route RCT2020
  8. GE buprenorphine register audit2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Perioperative/postoperative analgesia with exact Vetergesic Multidose 0.3 mg/ml
7.7/10
Good
vetman assessment

Vetergesic Multidose

0.3 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeCat · Perioperative/postoperative analgesia with exact Vetergesic Multidose 0.3 mg/ml · IM,IV
Care settingVeterinary perioperative care with controlled-drug custody, multimodal analgesia, formal pain scoring and cardiorespiratory monitoring
vetman score 7.7/10 Good
Evidence confidence: High Georgia: No · Verified on 22 Oct 2026

A well-defined authorised clinic opioid with direct multicentre feline evidence; strong for monitored postoperative use when the one-repeat ceiling and respiratory/behavioural effects are respected.

Regulatory and scientific credibility9.0/10

Exact current GB/European authorisations identify Ceva, the 10 ml multidose formulation, dog/cat species and IM/IV routes. The exact product is absent in GE/US.

Clinical efficacy8.0/10

The exact postoperative label, a 153-cat multicentre randomised product trial and additional perioperative evidence provide strong direct support.

Safety and tolerability6.5/10

Established monitored opioid use, but respiratory/cardiovascular depression, variable response, organ-dysfunction cautions, interactions and incomplete antagonist reversal constrain safety.

Clinical practicality7.0/10

IM/IV flexibility and a multidose vial suit hospital use. Tiny microgram doses require an accurately graduated syringe, strict repeat logic and controlled-drug governance; clinic administration itself is not penalised.

Full-course cost-effectiveness-

Current exact Georgian price/availability and a comparable treatment-period cost are not verified; cost is excluded.

Important safety and use flags

  • MICROGRAMS, not milligrams: 10–20 micrograms/kg equals 0.01–0.02 mg/kg and 0.03–0.06 ml/kg of this 0.3 mg/ml product. A unit error can be catastrophic.
  • This is exact Vetergesic Multidose: 10 ml vial, chlorocresol preservative, IM/IV. Do not substitute the separate IM-only 1 ml ampoules or US Simbadol/Zorbium concentrations and regimens.
  • Cats may receive only one repeat after 1–2 hours. Long-term safety beyond five consecutive days is not established; do not turn the label into an open-ended q1–2h schedule.
  • Use formal pain scoring and multimodal analgesia. Individual opioid response varies and a repeat dose may fail; provide rescue analgesia rather than accepting uncontrolled pain.
  • Monitor respiratory rate/effort, oxygenation, heart rate, blood pressure, temperature, sedation and recovery. Risk rises with impaired respiration, shock or renal, cardiac, hepatic/biliary dysfunction.
  • Do not administer intrathecally or epidurally, and do not use pre-operatively for caesarean section. Lactation use is not recommended; pregnancy requires a benefit-risk decision.
  • Other centrally acting sedatives can augment heart-rate and respiratory depression; reduce companion sedative doses and monitor. Do not combine casually with other opioids, including methadone or butorphanol.
  • Naloxone or respiratory stimulants may help, but opioid antagonists may not fully reverse buprenorphine and repeat dosing/infusion can be needed because of its duration. Support ventilation and circulation.
  • Mydriasis and euphoria/excitement behaviours such as purring, pacing and rubbing are common label effects; distinguish them from pain or dysphoria and continue objective pain assessment.
  • This is a high-risk controlled opioid. Maintain lawful procurement, secure storage, access/usage logs, reconciliation and witnessed disposal. Product registration does not remove controlled-drug obligations.
Assessment sources
  1. VMD SPC 20252025
  2. Vetergesic Multidose VMD record2026
  3. Vetergesic Multidose UPD record2026
  4. Vetergesic ampoule comparator2025
  5. WSAVA pain guideline 20222022
  6. Feline Vetergesic multicentre RCT2009
  7. FDA Zorbium formulation control2022
  8. GE buprenorphine register audit2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Buprenorphine0.3 mg/ml
Formulation Type
Solution
Administration route
Intramuscular, Intravenous
Manufacturer
Ceva Sante Animale · France
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ FR/V/0368/001
Verified on: 22 Oct 2026
 UK Yes, veterinary
№ Vm 14966/5029
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
Yes
Listed under the Georgian narcotics law (Annex 1) or the Minister's Order No. 22/n. The legal text is in Georgian.
Verified on: 16 Oct 2026
Information not fully verified Exact 10 ml multidose vial for IM or IV use. Dose in MICROGRAMS: 10–20 micrograms/kg equals 0.03–0.06 ml/kg. Dog repeat interval depends on dose; cats may receive only one repeat after 1–2 hours. Use an accurately graduated syringe and titrate subsequent analgesia to formal pain assessment.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗